Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome
Key Highlights
- ➤NICE expands funded IMCIVREE access to adults with genetically confirmed BBS
- ➤Updated guidance follows additional clinical, real-world and longer-term treatment evidence
- ➤NHS continues funding IMCIVREE for BBS children ages two to five in England and Wales
Expert Statements
Philip Beales, Emeritus Professor of Molecular Genetics and Genomic Medicine at University College London
“This updated recommendation is welcome news for adults in England, Wales and Northern Ireland living with Bardet-Biedl syndrome.”
Philip Beales, Emeritus Professor of Molecular Genetics and Genomic Medicine at University College London
“BBS is a lifelong disease, and adults continue to experience the significant burden of hyperphagia and obesity throughout their lives.”
Philip Beales, Emeritus Professor of Molecular Genetics and Genomic Medicine at University College London
“Expanding access to setmelanotide means more people living with BBS will have the opportunity to receive treatment.”
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome --
BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE(®) (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).
Get started
Create a free account to read the full story.